Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Caprin-1 inhibitor
DRUG CLASS:
Caprin-1 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
TRK-950 (2)
TRK-950 (2)
›
Associations
(2)
News
Trials
Filter by
Latest
3ms
A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=19, Recruiting, Toray Industries, Inc | Active, not recruiting --> Recruiting
3 months ago
Enrollment open
|
Opdivo (nivolumab) • TRK-950
3ms
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=187, Recruiting, Toray Industries, Inc | Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
3 months ago
Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium • Zyclara (imiquimod) • TRK-950
4ms
A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=7, Active, not recruiting, Toray Industries, Inc
4 months ago
Trial completion date • Trial primary completion date • Metastases
|
TRK-950
4ms
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=169, Recruiting, Toray Industries, Inc
4 months ago
Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • topotecan • leucovorin calcium • Zyclara (imiquimod) • TRK-950
5ms
A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (ASCO-GI 2024)
4, suppl. Clinical trial information: NCT06038578.
5 months ago
Clinical • P2 data • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • CAPRIN1 (Cell Cycle Associated Protein 1)
|
HER-2 positive • CAPRIN-1 expression
|
paclitaxel • Cyramza (ramucirumab) • TRK-950
6ms
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=169, Recruiting, Toray Industries, Inc | Phase classification: P1b --> P1
6 months ago
Phase classification • Metastases
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • topotecan • leucovorin calcium • Zyclara (imiquimod) • TRK-950
7ms
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer (clinicaltrials.gov)
P2, N=146, Recruiting, Toray Industries, Inc | Not yet recruiting --> Recruiting
7 months ago
Enrollment open • Combination therapy
|
CAPRIN1 (Cell Cycle Associated Protein 1)
|
paclitaxel • Cyramza (ramucirumab) • TRK-950
8ms
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer (clinicaltrials.gov)
P2, N=146, Not yet recruiting, Toray Industries, Inc
8 months ago
New P2 trial • Combination therapy
|
CAPRIN1 (Cell Cycle Associated Protein 1)
|
paclitaxel • Cyramza (ramucirumab) • TRK-950
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login